Skip to main content
Menu

Select a tool from the sidebar

Portfolio
Loading...
Sign In Get Started
Eli Lilly and Company (LLY)
LLY
Eli Lilly and Company (LLY)
1188.7200 $
+31.2300 (%+2.70)
Overview
Technicals
Financial Statements
Comments
Archive

LLY: Eli Lilly and Company Financials

Income statement, balance sheet, cash flow and financial performance data for Eli Lilly and Company.

Eli Lilly and Company Income Statement

Chart
Gross margin TTM
83.79%
Operating margin TTM
45.56%
Net profit margin TTM
31.66%
Return on investment TTM
77.78%
Period end31/12/202531/12/202431/12/202331/12/2022
Total revenue65,179,000,00045,042,700,00034,124,100,00028,541,400,000
Operating income29,696,000,00017,501,700,00010,787,300,0008,653,300,000
Net income20,638,300,00010,590,000,0005,240,400,0006,244,800,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Total revenue65,179,000,00045,042,700,00034,124,100,00028,541,400,000
Cost of revenue10,564,000,0008,418,300,0007,082,200,0006,629,800,000
Gross profit54,615,000,00036,624,400,00027,041,900,00021,911,600,000
Research and development expenses13,337,500,00010,990,600,0009,313,400,0007,190,800,000
General and administrative expenses11,094,000,0008,132,100,0006,941,200,0006,067,500,000
Selling and marketing expenses0000
Selling, general and administrative expenses11,094,000,0008,132,100,0006,941,200,0006,067,500,000
Other expenses487,500,000000
Operating expenses24,919,000,00019,122,700,00016,254,600,00013,258,300,000
Cost and expenses35,483,000,00027,541,000,00023,336,800,00019,888,100,000
Net interest income-642,000,000-605,400,000-312,300,000-268,800,000
Interest income153,300,000175,200,000173,600,00062,800,000
Interest expense795,300,000780,600,000485,900,000331,600,000
Depreciation and amortization1,563,500,0001,766,600,0001,527,300,0001,522,500,000
EBITDA27,936,500,00015,227,600,0008,567,800,0008,660,500,000
EBIT26,373,000,00013,461,000,0007,040,500,0007,138,000,000
Non-operating income (excl. interest)3,323,000,0004,040,700,0003,746,800,0001,515,300,000
Operating income29,696,000,00017,501,700,00010,787,300,0008,653,300,000
Total other income/expenses (net)-3,965,000,000-4,821,300,000-4,232,700,000-1,846,900,000
Income before tax25,729,900,00012,680,400,0006,554,600,0006,806,400,000
Income tax expense5,091,600,0002,090,400,0001,314,200,000561,600,000
Net income from continuing operations20,638,300,00010,590,000,0005,240,400,0006,244,800,000
Net income from discontinued operations0000
Other adjustments to net income0000
Net income20,638,300,00010,590,000,0005,240,400,0006,244,800,000
Net income deductions0000
Bottom line net income20,638,300,00010,590,000,0005,240,400,0006,244,800,000
EPS231267
Diluted EPS231267
Weighted average shares outstanding898,002,000900,605,000899,379,000950,182,000
Weighted average diluted shares outstanding898,002,000904,059,000903,284,000950,182,000

Eli Lilly and Company Balance Sheet

Period endTotal assetsTotal liabilities & equity
31/12/2025112,476,000,00085,941,000,000
31/12/202478,714,900,00064,443,300,000
31/12/202364,006,300,00053,142,600,000
31/12/202249,489,800,00038,714,400,000
Long-term debt / assets MRQ
40,868,000,000%
Period end31/12/202531/12/202431/12/202331/12/2022
Total assets112,476,000,00078,714,900,00064,006,300,00049,489,800,000
Total liabilities85,941,000,00064,443,300,00053,142,600,00038,714,400,000
Total equity26,535,000,00014,192,100,00010,771,900,00010,649,800,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Cash and cash equivalents7,163,000,0003,268,400,0002,818,600,0002,067,000,000
Short-term investments105,000,000154,800,000109,100,000144,800,000
Cash and short-term investments7,268,000,0003,423,200,0002,927,700,0002,211,800,000
Net receivables20,155,000,00013,275,400,00011,336,200,0008,558,900,000
Accounts receivable17,760,000,00011,005,700,0009,090,500,0006,896,000,000
Other receivables2,395,000,0002,269,700,0002,245,700,0001,662,900,000
Inventory13,744,000,0007,589,200,0005,772,800,0004,309,700,000
Prepaid expenses14,315,000,0008,340,500,0005,540,800,0002,946,800,000
Other current assets147,000,000111,400,000149,500,0007,300,000
Total current assets55,629,000,00032,739,700,00025,727,000,00018,034,500,000
Property, plant and equipment (net)24,675,000,00017,102,400,00012,913,600,00010,144,000,000
Goodwill5,898,000,0005,770,300,0004,939,700,0004,073,000,000
Intangible assets6,521,000,0006,166,300,0006,906,600,0007,206,600,000
Goodwill and intangible assets12,419,000,00011,936,600,00011,846,300,00011,279,600,000
Long-term investments2,802,000,0003,215,900,0003,052,200,0002,901,800,000
Tax assets9,959,000,0008,000,600,0005,477,300,0002,792,900,000
Other non-current assets6,992,000,0005,719,700,0004,989,900,0004,337,000,000
Total non-current assets56,847,000,00045,975,200,00038,279,300,00031,455,300,000
Other assets0000
Total assets112,476,000,00078,714,900,00064,006,300,00049,489,800,000
Total payables5,379,000,0004,574,900,0003,768,000,0002,947,800,000
Accounts payable5,379,000,0003,228,600,0002,598,800,0001,930,600,000
Other payables01,346,300,0001,169,200,0001,017,200,000
Accrued expenses011,539,300,00011,689,000,0008,784,100,000
Short-term debt1,635,000,0005,117,100,0006,904,500,0001,501,100,000
Capital lease obligations (current)0000
Tax payables5,875,000,00003,849,200,000475,100,000
Deferred revenue0000
Other current liabilities28,214,000,0007,145,300,0004,931,700,0003,905,200,000
Total current liabilities35,228,000,00028,376,600,00027,293,200,00017,138,200,000
Long-term debt40,868,000,00028,527,100,00018,320,800,00014,737,500,000
Capital lease obligations (non-current)0000
Deferred revenue (non-current)0000
Deferred tax liabilities (non-current)00087,300,000
Other non-current liabilities9,845,000,0007,539,600,0007,528,600,0006,751,400,000
Total non-current liabilities50,713,000,00036,066,700,00025,849,400,00021,576,200,000
Other liabilities0000
Capital lease obligations0000
Total liabilities85,941,000,00064,443,300,00053,142,600,00038,714,400,000
Treasury stock0-49,500,000-44,200,000-50,500,000
Preferred stock0000
Common stock590,000,000592,400,000593,600,000594,100,000
Retained earnings24,470,000,00013,545,000,00010,312,300,00010,042,600,000
Additional paid-in capital7,346,000,0007,439,300,0007,250,400,0006,921,400,000
Accumulated other comprehensive income/loss-2,880,000,000-4,321,900,000-4,327,000,000-3,844,600,000
Other stockholders' equity-2,991,000,000-3,013,200,000-3,013,200,000-3,013,200,000
Total stockholders' equity26,535,000,00014,192,100,00010,771,900,00010,649,800,000
Total equity26,535,000,00014,271,600,00010,863,700,00010,775,400,000
Minority interest079,500,00091,800,000125,600,000
Total liabilities and total equity112,476,000,00078,714,900,00064,006,300,00049,489,800,000
Total investments2,907,000,0003,370,700,0003,161,300,0003,046,600,000
Total debt42,503,000,00033,644,200,00025,225,300,00016,238,600,000
Net debt35,340,000,00030,375,800,00022,406,700,00014,171,600,000

Eli Lilly and Company Cash Flow Statement

Chart
Period end31/12/202531/12/202431/12/202331/12/2022
Cash from operations16,813,000,0008,817,900,0004,240,100,0007,585,700,000
Cash from investing-10,972,000,000-9,301,500,000-7,152,700,000-3,762,900,000
Cash from financing-2,213,000,0001,230,100,0003,495,600,000-5,406,700,000
Net change in cash4,000,000,000449,800,000751,600,000-1,751,500,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Net income20,640,000,00010,590,000,0005,240,400,0006,244,800,000
Depreciation and amortization1,997,000,0001,766,600,0001,527,300,0001,522,500,000
Deferred income tax-1,707,000,000-2,683,100,000-2,341,000,000-2,185,200,000
Stock-based compensation626,000,000645,600,000628,500,000371,100,000
Change in working capital-8,093,000,000-5,385,000,000-3,055,000,000-800,000
Accounts receivable-7,000,000,000-2,155,200,000-2,451,000,000-299,600,000
Inventory-4,671,000,000-2,507,400,000-1,425,000,000-599,700,000
Accounts payable10,187,000,0002,608,800,0004,274,400,0001,331,700,000
Other working capital-6,609,000,000-3,331,200,000-3,453,400,000-433,200,000
Other non-cash items3,350,000,0003,883,800,0002,239,900,0001,633,300,000
Net cash from operating activities16,813,000,0008,817,900,0004,240,100,0007,585,700,000
Investments in property, plant and equipment-7,841,000,000-5,057,800,000-3,447,600,000-1,854,300,000
Acquisitions (net)-661,000,000-947,700,000-1,044,300,000-327,200,000
Purchases of investments-645,000,000-775,800,000-829,000,000-707,600,000
Sales/maturities of investments964,000,000522,500,000700,300,000463,600,000
Other investing activities-2,789,000,000-3,042,700,000-2,532,100,000-1,337,400,000
Net cash from investing activities-10,972,000,000-9,301,500,000-7,152,700,000-3,762,900,000
Net debt issuance8,051,000,0008,901,100,0008,649,900,000-62,000,000
Long-term net debt issuance12,389,000,00010,752,900,0003,958,500,000-1,560,000,000
Short-term net debt issuance-4,338,000,000-1,851,800,0004,691,400,0001,498,000,000
Net stock issuance-4,108,000,000-2,500,000,000-750,000,000-1,500,000,000
Net common stock issuance-4,108,000,000-2,500,000,000-750,000,000-1,500,000,000
Common stock issuance0000
Common stock repurchased-4,108,000,000-2,500,000,000-750,000,000-1,500,000,000
Net preferred stock issuance0000
Net dividends paid-5,384,000,000-4,680,400,000-4,069,300,000-3,535,800,000
Common dividends paid-5,384,000,000-4,680,400,000-4,069,300,000-3,535,800,000
Preferred dividends paid0000
Other financing activities-772,000,000-490,600,000-335,000,000-308,900,000
Net cash from financing activities-2,213,000,0001,230,100,0003,495,600,000-5,406,700,000
Effect of FX changes on cash372,000,000-296,700,000168,600,000-167,600,000
Net change in cash4,000,000,000449,800,000751,600,000-1,751,500,000
Cash at end of period7,268,000,0003,268,400,0002,818,600,0002,067,000,000
Cash at beginning of period3,268,000,0002,818,600,0002,067,000,0003,818,500,000
Operating cash flow16,813,000,0008,817,900,0004,240,100,0007,585,700,000
Capital expenditure-7,841,000,000-8,403,600,000-7,392,100,000-2,985,300,000
Free cash flow8,972,000,000414,300,000-3,152,000,0004,600,400,000
Income taxes paid0000
Interest paid0000